Sentiment Summary
Recent Events
Ex-dividend date (2026-06-24) for the proposed final dividend of HKD 0.15 per share for the fiscal year 2025, scheduled.
Ex-dividend date for final dividend of HK$0.05 per share for the year ended December 31, 2025, scheduled for 2026-06-24. Dividend adjustment typically results in a ~1% price impact, scheduled.
Annual General Meeting scheduled for June 16, 2026, where proposals such as the annual dividend will be voted on; AGMs typically impact stock prices by approximately 5% scheduled
Q4 and full fiscal year 2026 earnings results announcement on 2026-06-03. Fiscal year ends 2026-04-24. Medium importance estimated as earnings typically drive significant price movement; scheduled.
Google's annual I/O developer conference is scheduled for May 19-20, 2026, where new developments in AI and Android are expected. Medium impact estimated due to potential major product reveals, expected.
Publication of full-year results for the 2025/26 financial year; annual earnings reports typically result in price volatility exceeding 10% scheduled
Q1 2026 earnings release is scheduled. Estimated importance is High based on typical market reaction to earnings reports scheduled
Interim report for Q2 2025/26 scheduled to be released. Impact is estimated as Medium as earnings reports are key volatility drivers.
First-quarter 2026 financial results and conference call for 2026-05-06 scheduled. Low impact expected as it is a routine announcement.
First quarter 2026 financial results are scheduled to be released after the close of trading on May 4, 2026. Impact is estimated as neutral pending the actual report, scheduled.
Integer Holdings is scheduled to release its financial results for the first quarter of 2026 on April 30, 2026, with a conference call to follow; impact is estimated as neutral as this is a standard reporting event scheduled.
Q1 2026 earnings release is scheduled. A medium impact is estimated as earnings reports typically drive significant price movement.
Alphabet's Q1 2026 earnings results and conference call are scheduled for April 29, 2026. Low impact estimated for this routine announcement, scheduled.
First quarter 2026 earnings results are scheduled to be announced on 2026-04-28. Estimated Medium importance as quarterly earnings typically result in a 5-10% price impact scheduled.
The company scheduled a board of directors meeting for April 28, 2026, to approve and announce the first quarter results for the period ending March 31, 2026, expected.
Board meeting to approve Q1 2026 unaudited financial results scheduled. Medium importance estimated due to historical price sensitivity to earnings reports.
First quarter 2026 earnings release for the period ended March 31, 2026, is scheduled for April 27, 2026. Market anticipation for the quarterly performance update is estimated to result in a 5% price impact.
Estimated low impact (<5%) as the date announcement is routine; first quarter 2026 earnings results are scheduled.
Board meeting to approve and publish the first quarter 2026 financial results; market impact is estimated at ~5% as quarterly results often drive significant price volatility, expected.
Q1 2026 earnings release is scheduled for April 22, 2026. Analysts forecast EPS of approximately $0.79-$0.80 on revenue of $5.19-$5.20 billion, forecasted. The price impact is expected.
Abbott is scheduled to announce its Q1 2026 financial results on April 16, 2026, before the market opens; analysts forecast EPS of $1.15 and revenue of $11.0 billion; earnings releases typically result in a ~5% price impact scheduled.
RemeGen announced on April 15, 2026, the receipt of a US$650 million upfront payment from AbbVie for the exclusive licensing of RC148; High importance estimated due to the massive cash infusion likely resulting in >10% price impact.
The company's antibody-drug conjugate, SYS6051, received approval from China's National Medical Products Administration (NMPA) to start clinical trials for treating advanced solid tumors.
On April 15, 2026, it was reported that the Centers for Medicare & Medicaid Services (CMS) proposed a New Technology Add-on Payment (NTAP) for the company's delirium monitoring system, set to begin in fiscal year 2027; a 5% price impact is estimated due to improved reimbursement prospects, expected.
Announced that its subsidiary received approval from China's National Medical Products Administration (NMPA) for the clinical trial of HRS-7156 tablets, a self-developed Class 1 new drug for heart failure. Market impact is estimated at ~1% as clinical trial approvals for early-stage drugs typically have limited immediate price impact.
Aptoide filed an antitrust lawsuit against Google on April 15, 2026, alleging abuse of dominance in the Android app distribution market.
Announced positive results from a Phase II study of sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab for gynecologic cancers, presented at the 2026 SGO Annual Meeting. The data showed promising efficacy and a manageable safety profile.
The "-B" marker was removed from the company's stock code on the Hong Kong Stock Exchange, effective April 14, 2026. This signifies the company has met the exchange's main board revenue and market capitalization requirements for established companies.
On April 14, 2026, presented positive one-year clinical trial results for its Farapulse PFA system in treating persistent atrial fibrillation, showing a 65% efficacy rate with a favorable safety profile. The price impact is estimated.
Johnson & Johnson reported Q1 2026 sales of $24.1 billion and adjusted EPS of $2.70, beating analyst estimates, and raised its full-year guidance with a 3.1% dividend increase. Estimated 5% impact due to strong earnings and guidance; expected.
Announced positive results from the Phase 3 BRUIN CLL-322 trial, where Jaypirca in combination with venetoclax and rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia (CLL).
Announced on April 13, 2026, that its subsidiary Ailux appointed Professor Maria Belvisi, former SVP at AstraZeneca, as Chief Scientific Officer to lead a new UK research site. Low importance as subsidiary appointments typically result in >=1% price impact, scheduled.
On April 12, 2026, partner GSK presented highly positive Phase 1b clinical trial results for mocertatug rezetecan (HS-20093), an antibody-drug conjugate licensed from Hansoh, showing a 62% overall response rate in platinum-resistant ovarian cancer and 67% in endometrial cancer. GSK plans to advance to five Phase 3 trials.
A major shareholder, Shanghai Tanying Investment, let its share reduction plan expire without selling any shares on April 10, 2026, which was positively received by the market.
On April 10, 2026, RemeGen announced that China's NMPA approved the new drug application for Disitamab Vedotin (RC48); Medium importance estimated as core product approval typically drives a 5-10% market reaction.
Announced that its subsidiary received approval from China's NMPA for the clinical trial of HRS-5765 tablets, a self-developed Class 1 new drug for heart failure. Market impact is estimated at ~1% as clinical trial approvals for early-stage drugs typically have limited immediate price impact.
Subsidiary's Flurbiprofen Ester Injectable drug registration approval from China's NMPA on 2026-04-10. Estimated Low importance as single drug approvals typically have a 1-5% price impact expected.